Details for New Drug Application (NDA): 201280
✉ Email this page to a colleague
The generic ingredient in TRADJENTA is linagliptin. There are nineteen drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the linagliptin profile page.
Summary for 201280
Tradename: | TRADJENTA |
Applicant: | Boehringer Ingelheim |
Ingredient: | linagliptin |
Patents: | 9 |
Pharmacology for NDA: 201280
Mechanism of Action | Dipeptidyl Peptidase 4 Inhibitors |
Medical Subject Heading (MeSH) Categories for 201280
Suppliers and Packaging for NDA: 201280
Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
---|---|---|---|---|---|---|---|---|
TRADJENTA | linagliptin | TABLET;ORAL | 201280 | NDA | Boehringer Ingelheim Pharmaceuticals, Inc. | 0597-0140 | 0597-0140-30 | 30 TABLET, FILM COATED in 1 BOTTLE (0597-0140-30) |
TRADJENTA | linagliptin | TABLET;ORAL | 201280 | NDA | Boehringer Ingelheim Pharmaceuticals, Inc. | 0597-0140 | 0597-0140-61 | 100 BLISTER PACK in 1 CARTON (0597-0140-61) / 1 TABLET, FILM COATED in 1 BLISTER PACK |
Profile for product number 001
Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | 5MG | ||||
Approval Date: | May 2, 2011 | TE: | AB | RLD: | Yes | ||||
Regulatory Exclusivity Expiration: | Dec 20, 2026 | ||||||||
Regulatory Exclusivity Use: | PEDIATRIC EXCLUSIVITY | ||||||||
Regulatory Exclusivity Expiration: | Jun 20, 2026 | ||||||||
Regulatory Exclusivity Use: | REVISIONS TO THE PEDIATRIC USE SUBSECTION OF LABELING TO INCLUDE THE RESULTS FROM CLINICAL STUDY 1218-0091, CONDUCTED TO FULFILL A PEDIATRIC WRITTEN REQUEST | ||||||||
Patent: | ⤷ Sign Up | Patent Expiration: | Feb 5, 2030 | Product Flag? | Substance Flag? | Delist Request? | Y |
Expired US Patents for NDA 201280
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Boehringer Ingelheim | TRADJENTA | linagliptin | TABLET;ORAL | 201280-001 | May 2, 2011 | ⤷ Sign Up | ⤷ Sign Up |
Boehringer Ingelheim | TRADJENTA | linagliptin | TABLET;ORAL | 201280-001 | May 2, 2011 | ⤷ Sign Up | ⤷ Sign Up |
Boehringer Ingelheim | TRADJENTA | linagliptin | TABLET;ORAL | 201280-001 | May 2, 2011 | ⤷ Sign Up | ⤷ Sign Up |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Complete Access Available with Subscription